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parison cohort ($76 vs. $128) and remained favorable 
for capecitabine versus individual therapy subgroups
(5FULV: $75, 5FULV then CPT: $162, and 5FULV plus
CPT: $228). The total cost for chemotherapy and 
supportive care with capecitabine was much lower per
patient ($3,264 vs. $10,112). Savings with capecitabine
were primarily realized from reduced cost of chemo-
therapy ($2,416 vs. $8,499), anti-emetics ($83 vs. $999)
and anti-infective agents ($19 vs. $69) relative to 
comparison therapies.
CONCLUSION: Oral administration of capecitabine
offers similar clinical outcomes and superior cost-
effectiveness relative to comparison therapies.
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OBJECTIVES: Systemic fungal infections are becoming
increasingly common, particularly among immunocom-
promised patients. Our objective was to examine the 
clinical and economic effects of these infections.
METHODS: This study involved a retrospective cohort
analysis of the excess mortality, length of stay (LOS), and
costs attributable to serious fungal infections among 
hospitalized elderly patients with acute myeloid leukemia
(AML). Linked data from the Surveillance, Epidemiology
and End Results (SEER) Program of the National Cancer
Institute and Medicare claims data were used for the
analysis. Study cohorts included patients aged 65 years
and older who were newly diagnosed with AML between
1991 and 1996 and who developed a serious fungal 
infection (deﬁned by selected ICD-9-CM codes) during an
inpatient hospitalization (N = 80), and matched (1 :1)
hospitalized controls who did not develop a fungal 
infection. Matching variables included factors expected to
inﬂuence LOS, including age, geographic region, timing
of hospitalization, recent treatment with chemotherapy,
and presence of a concomitant bacterial infection.
RESULTS: Average age in both cohorts was 72.9 years.
Groups were similar on key non-matched characteristics,
including chronic comorbidities and metropolitan 
residence. Patients with serious fungal infections had
higher in-hospital mortality than controls (36% vs. 25%;
p = 0.12), longer LOS (mean ± SD: 31 ± 19 vs. 20 ± 15;
median: 27 vs. 16; p < 0.0001) and more ICU days (mean
± SD: 2.7 ± 7 vs. 1.9 ± 6; p = 0.22). Medicare payments
(in 1998 US dollars) also were signiﬁcantly higher among
patients with fungal infections (mean ± SD: $34,217 ±
31,821 vs. $22,547 ± 17,000 for controls; median:
$25,930 vs. $19,661; p < 0.01), with a larger difference
noted between groups when mean hospital charges were
assessed ($110,582 vs. $60,259; p < 0.0001). The rate of
rehospitalization for any reason within 30 days was
nearly identical in the 2 groups (47%).
CONCLUSIONS: The excess mortality and LOS 
attributable to serious fungal infections are substantial, a
ﬁnding likely to be of interest to clinicians and hospital
administrators.
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OBJECTIVE: To assess the frequency and troublesome-
ness of side-effects of chemotherapy for ovarian cancer as
they affect patients’ physical and social health and 
treatment compliance.
METHOD: A questionnaire was developed based on a
literature review of reactions to chemotherapy and pub-
lished product information on side-effects The question-
naire was pilot tested for time, ease of understanding and
surface validity. Trained clinical interviewers adminis-
tered in-depth face-to-face interviews to 29 women with
ovarian cancer. Participants rated 28 potential side effects
on a 5 point Likert Scale ranging from 0 (Not at all 
troublesome) to 4 (Extremely troublesome), For side-
effects rated at least “slightly troublesome”, a series of
open ended follow-up questions were asked to more fully
understand the response. Chart reviews were conducted
to verify diagnosis and treatment regimens.
RESULTS: Ages ranged from 25 to 78 years (x = 53). The
most frequently reported side-effects (hair loss [n = 25],
general weakness [n = 23], numbness [n = 20], nausea [n
= 19] and infusion reaction [n = 18]) were not perceived
as most troublesome. Means for most troublesome 
side-effects were: infections (x = 3.2), pain in hands and
feet (x = 3.0), constipation (x = 3.0), vomiting (x = 3.0)
and sores in the mouth and throat (x = 2.8). Results indi-
cated side-effects are an extremely common and often
under-treated component of chemotherapy. Many
respondents were bothered that health-care providers
neither gave sufﬁcient warning about the troublesomeness
of speciﬁc side-effects nor provided practical advice on
how symptoms could be ameliorated.
CONCLUSION: The effectiveness of chemotherapy 
regimens as measured through impact on survival as well
as more subjective measures such as quality of life tradi-
tionally do not take into account the signiﬁcant impact
of side-effects on physical and social functioning and
treatment compliance. The nature of side-effects contin-
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ues to change as new chemotherapy agents are developed.
These results suggest that therapies that avoid or amelio-
rate the most troublesome side-effects would be preferred
agents.
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OBJECTIVES: Various disease speciﬁc instruments exist
to measure treatment satisfaction and patient preference.
Subsequently, data from these instruments have been used
to differentiate treatment options. Several measurements
exist to assess satisfaction with oncology care, but few
tools exist to measure satisfaction with or preferences for
oncology treatments. As the paradigm in oncology shifts
from treating and managing cancer as a terminal disease
to a chronic disease and with an increasing number of
treatment options, the need to assess patients’ perceptions
and preferences regarding treatment becomes more
evident. The purpose of this study was to review and
compare characteristics of instruments within oncology
studies that assessed aspects of treatment satisfaction and
patient preference.
METHODS: Publications involving oncology patients,
treatment satisfaction, and patient preference were 
identiﬁed through the search of available literature 
within MEDLINE and CANCERLIT.
RESULTS: The search did not identify a comprehensive
patient treatment satisfaction instrument. Selected 
ﬁndings included the preference for: oral rather than
intravenous medication; treatment at home over outpa-
tient clinic care; and follow-up care with primary physi-
cians rather than oncologists. Findings with respect to
patient preference for using chemotherapy revealed that
survival and toxicity trade-off differed between patients
with different tumor types. Breast cancer patients are
more willing to accept aggressive treatment with severe
side effects in exchange for minimal to no increase in sur-
vival rates. Non-small cell lung cancer patients, on the
other hand, are not as willing to undergo chemotherapy
and prefer a signiﬁcant increase in survival duration with
minimal toxicity.
CONCLUSIONS: Various techniques have been used to
assess aspects of patient satisfaction and preference with
treatment. However, the application of these instruments
in oncology is not yet widespread. The availability of a
tool that combines these measurements into one instru-
ment would be valuable when evaluating new therapies
compared to standard of care regimens.
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OBJECTIVE: To examine the relative contributions 
of mental and physical health to evaluations of health
preference for advanced-stage cancer patients in a 
longitudinal setting.
METHODS: We compared changes in the Physical 
Component Summary (PCS) and Mental Component
Summary (MCS) scores of the Medical Outcomes Survey
Short Form (SF-36) with changes in the EuroQoL visual
analogue scale (VAS) for a sample of advanced-stage
cancer patients. Using data collected at baseline and 3-
month followup in a multicenter study of 328 cancer
patients eligible for phase I clinical trials, we examined
correlations among change-from-baseline scores for the
PCS, MCS, and VAS.
RESULTS: Mean age was 57.5 years; 10 different types
of malignancies were represented in the sample. Com-
pleters (144 patients who completed both baseline and
follow-up questionnaires) had a signiﬁcantly (p = 0.01)
higher average baseline PCS score (M = 41.5, SD+/- 10.1)
than non-completers (M = 38.3, SD+/- 12.3), whereas
baseline MCS and VAS scores did not differ between the
two groups (p = 0.74 and 0.28, respectively). Change-
from-baseline in the VAS (M = -5.7, SD+/-21.8) was 
positively correlated (r = 0.34, p = 0.0002) with changes
in the PCS (M = -4.1, SD+/-9.9), and was positively 
correlated (r = 0.23, p = 0.0123) with changes in the 
MCS (M = -1.1, SD+/-9.7). While the distribution of 
VAS change scores was more piqued, there was greater
variability in MCS and PCS change scores.
CONCLUSIONS: Changes in overall mental and physi-
cal health contribute approximately equally to changes 
in advanced-stage cancer patients’ preferences for their
current health states. Our ability to detect strong corre-
lations between changes in the VAS preference measure
and changes in the MCS and PCS health status measures
was limited by lack of variability in change scores for 
the preference measure used. Further research should
examine longitudinal relationships between other prefer-
ence measures (i.e. standard gamble and time-tradeoff)
and generic health status measures.
